Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes

Molecular and Cellular Biology

Volumn 31, Issue 11, 2011, Pages 2349-2363

  Pillai, Vinodkumar B ^a   Sundaresan, Nagalingam R ^a   Samant, Sadhana A ^a   Wolfgeher, Don ^b   Trivedi, Chinmay M ^c   Gupta, Mahesh P ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE 3; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ACETYLATION; ARTICLE; CELL STRESS; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ACETYLATION; ACETYLTRANSFERASES; ADENOSINE TRIPHOSPHATE; ANIMALS; CELLS, CULTURED; HEK293 CELLS; HELA CELLS; HISTONE DEACETYLASES; HUMANS; HYPERTROPHY; MASS SPECTROMETRY; MICE; MYOCYTES, CARDIAC; P300-CBP TRANSCRIPTION FACTORS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; STRESS, PHYSIOLOGICAL;

EID: 79958033203     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01205-10     Document Type: Article

References (59)

1. Ataullakhanov, F. I., and V. M. Vitvitsky. 2002. What determines the intracellular ATP concentration. Biosci. Rep. 22:501-511.
2. Aw, T. Y., B. S. Andersson, and D. P. Jones. 1987. Mitochondrial transmembrane ion distribution during anoxia. Am. J. Physiol. 252:C356-C361.
3. Batta, K., C. Das, S. Gadad, J. Shandilya, and T. Kundu. 2007. Reversible acetylation of non histone proteins: role in cellular function and disease. Subcell. Biochem. 41:193-212.
4. Brancho, D., et al. 2003. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 17:1969-1978.
5. Bratton, M. R., et al. 2009. Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis. 30:106-113.
6. Bueno, O. F., et al. 2000. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:6341-6350.
7. Bulavin, D. V., et al. 1999. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18:6845-6854.
8. Cook, S. A., P. H. Sugden, and A. Clerk. 1999. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J. Mol. Cell. Cardiol. 31:1429-1434.
9. Cui, Y., et al. 2004. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 64:9199-9208.
10. Garriga, J., Xie, H., Obradovic, Z., and Graña, X. 2010. Selective control of gene expression by CDK9 in human cells. J. Cell. Physiol. 222:200-208.
11. Ge, B., et al. 2002. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science. 295:1291-1294.
12. Gomes, P., S. P. Srinivas, W. Van Driessche, J. Vereecke, and B. Himpens. 2005. ATP release through connexin hemichannels in corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 46:1208-1218.
13. Guan, Z., S. Y. Buckman, A. P. Pentland, D. J. Templeton, and A. R. Morrison. 1998. Induction of cyclooxygenase-2 by the activated MEKK1-SEK1/MKK4-p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 273:12901-12908.
14. Gum, R. J., and P. R. Young. 1999. Identification of two distinct regions of p38 MAPK required for substrate binding and phosphorylation. Biochem. Biophys. Res. Commun. 266:284-289.
15. Gupta, A., V. P. Chacko, and R. G. Weiss. 2009. Abnormal energetics and ATP depletion in pressure-overload mouse hearts: in vivo high-energy phosphate concentration measures by noninvasive magnetic resonance. Am. J. Physiol. Heart Circ. Physiol. 297:H59-64.
16. Gusterson, R., et al. 2002. The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade. J. Biol. Chem. 277:2517-2524.
17. Gusterson, R. J., E. Jazrawi, I. M. Adcock, and D. S. Latchman. 2003. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J. Biol. Chem. 278:6838-6847.
18. Han, J., Y. Jiang, Z. Li, V. V. Kravchenko, and R. J. Ulevitch. 1997. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature. 386:296-299.
19. Han, J., J. D. Lee, L. Bibbs, and R. J. Ulevitch. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 265:808-811.
20. Haq, R., et al. 2002. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res. 62:5076-5082.
21. Haq, S., et al. 2001. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 103:670-677.
22. Hollenbach, E., et al. 2004. Inhibition of p38 MAP kinase- and RICK/NFkappaB-signaling suppresses inflammatory bowel disease. FASEB J. 18: 1550-1552.
23. Ivanov, V. N., and Z. Ronai. 2000. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression. Oncogene. 19:3003-3012.
24. Kenski, D. M., C. Zhang, M. von Zastrow, and K. M. Shokat. 2005. Chemical genetic engineering of G protein-coupled receptor kinase 2. J. Biol. Chem. 280:35051-35061.
25. Kouzarides, T. 2000. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19:1176-1179.
26. Kudoh, S., et al. 1998. Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice. J. Biol. Chem. 273:24037-24043.
27. Kuster, G. M., et al. 2005. Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation. 111:1192-1198.
28. Lan, F., J. M. Cacicedo, N. Ruderman, and Y. Ido. 2008. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. J. Biol. Chem. 283:27628-27635.
29. Leist, M., B. Single, A. F. Castoldi, S. Kuhnle, and P. Nicotera. 1997. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185:1481-1486.
30. Liang, Q., and J. D. Molkentin. 2003. Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J. Mol. Cell. Cardiol. 35:1385-1394.
31. Liao, P., et al. 2001. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 98: 12283-12288.
32. Ma, K., J. K. L. Chan, G. Zhu, and Z. Wu. 2005. Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity, and myogenic differentiation. Mol. Cell. Biol. 25:3575-3582.
33. Mahmud, D. L., et al. 2002. Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene. 21:1556-1562.
34. Mateo, F., et al. 2009. The transcriptional co-activator PCAF regulates cdk2 activity. Nucleic Acids Res. 37:7072-7084.
35. McMullen, M., R. Keller, M. Sussman, and K. Pumiglia. 2004. Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK//Pyk2. Oncogene. 23:1275-1282.
36. Miller, A. L., et al. 2005. p38 mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol. Endocrinol. 19:1569-1583.
37. Morley,1; S. J., and L. McKendrick. 1997. Involvement of stress-activated protein kinase and p38/RK mitogen-activated protein kinase signaling pathways in the enhanced phosphorylation of initiation factor 4E in NIH 3T3 cells. J. Biol. Chem. 272:17887-17893.
38. Mukherjee, S., et al. 2006. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science. 312:1211-1214.
39. Nishida, K., et al. 2004. p38 alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol. Cell. Biol. 24:10611-10620.
40. Petrich, B. G., and Y. Wang. 2004. Stress-activated MAP kinases in cardiac remodeling and heart failure: new insights from transgenic studies. Trends Cardiovasc. Med. 14:50-55.
41. Pillai, V. B., et al. 2010. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 285:3133-3144.
42. Raingeaud, J. L., et al. 1995. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270:7420-7426.
43. Rajamohan, S. B., et al. 2009. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol. Cell. Biol. 29:4116-4129.
44. Ramakrishnan, C., V. S. Dani, and T. Ramasarma. 2002. A conformational analysis of Walker motif A [GXXXXGKT (S)] in nucleotide-binding and other proteins. Protein Eng. 15:783-798.
45. Rouse, J., et al. 1994. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell. 78:1027-1037.
46. Sabò, A., M. Lusic, A. Cereseto, and M. Giacca. 2008. Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription. Mol. Cell. Biol. 28:2201-2212.
47. Saha, R. N., M. Jana, and K. Pahan. 2007. MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J. Immunol. 179:7101-7109.
48. Sakaguchi, K., et al. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831-2841.
49. Sawyer, D. B., et al. 2002. Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell. Cardiol. 34:379-388.
50. Sundaresan, N. R., et al. 2009. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119:2758-2771.
51. Takenaka, K., T. Moriguchi, and E. Nishida. 1998. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science. 280:599-602.
52. Takimoto, E., and D. A. Kass. 2007. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 49:241-248.
53. Trivedi, C. M., M. M. Lu, Q. Wang, and J. A. Epstein. 2008. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J. Biol. Chem. 283: 26484-26489.
54. Wang, R., P. Cherukuri, and J. Luo. 2005. Activation of Stat3 sequencespecific DNA binding and transcription by p300/CREB-binding proteinmediated acetylation. J. Biol. Chem. 280:11528-11534.
55. Wang, X.-Z., and D. Ron. 1996. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science. 272:1347-1349.
56. Webster, R. P., D. Brockman, and L. Myatt. 2006. Nitration of p38 MAPK in the placenta: association of nitration with reduced catalytic activity of p38 MAPK in pre-eclampsia. Mol. Hum. Reprod. 12:677-685.
57. Yanazume, T., et al. 2003. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol. 23:3593-3606.
58. Zhang, X., et al. 2004. Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol. Cell. Biol. 24:5106-5118.
59. Zhao, M., et al. 1999. Regulation of the MEF2 family of transcription factors by p38. Mol. Cell. Biol. 19:21-30.